SUMO2 and acute promyelocytic leukemia: The spleen is a hematopoietic organ enlarged upon leukemic cell invasion, rendering possible in vivo differential analysis of SUMO2 targets with altered (untreated APL) or restored (arsenic-treated APL) PML NBs formation.